Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 390

1.

Impaired dopamine- and adenosine-mediated signaling and plasticity in a novel rodent model for DYT25 dystonia.

Yu-Taeger L, Ott T, Bonsi P, Tomczak C, Wassouf Z, Martella G, Sciamanna G, Imbriani P, Ponterio G, Tassone A, Schulze-Hentrich JM, Goodchild R, Riess O, Pisani A, Grundmann-Hauser K, Nguyen HP.

Neurobiol Dis. 2019 Oct 30:104634. doi: 10.1016/j.nbd.2019.104634. [Epub ahead of print]

2.

Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD.

Singer E, Walter C, Fabbro D, Rageot D, Beaufils F, Wymann MP, Rischert N, Riess O, Hillmann P, Nguyen HP.

Neuropharmacology. 2019 Oct 14;162:107812. doi: 10.1016/j.neuropharm.2019.107812. [Epub ahead of print]

PMID:
31622602
3.

Author Correction: Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease.

Krashia P, Cordella A, Nobili A, La Barbera L, Federici M, Leuti A, Campanelli F, Natale G, Marino G, Calabrese V, Vedele F, Ghiglieri V, Picconi B, Di Lazzaro G, Schirinzi T, Sancesario G, Casadei N, Riess O, Bernardini S, Pisani A, Calabresi P, Viscomi MT, Serhan CN, Chiurchiù V, D'Amelio M, Mercuri NB.

Nat Commun. 2019 Oct 14;10(1):4725. doi: 10.1038/s41467-019-12538-2.

4.

Silhouette-Length-Scaled Gait Parameters for Motor Functional Analysis in Mice and Rats.

Timotius IK, Moceri S, Plank AC, Habermeyer J, Canneva F, Winkler J, Klucken J, Casadei N, Riess O, Eskofier B, von Hörsten S.

eNeuro. 2019 Nov 1;6(6). pii: ENEURO.0100-19.2019. doi: 10.1523/ENEURO.0100-19.2019. Print 2019 Nov/Dec.

5.

Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease.

Krashia P, Cordella A, Nobili A, La Barbera L, Federici M, Leuti A, Campanelli F, Natale G, Marino G, Calabrese V, Vedele F, Ghiglieri V, Picconi B, Di Lazzaro G, Schirinzi T, Sancesario G, Casadei N, Riess O, Bernardini S, Pisani A, Calabresi P, Viscomi MT, Serhan CN, Chiurchiù V, D'Amelio M, Mercuri NB.

Nat Commun. 2019 Sep 2;10(1):3945. doi: 10.1038/s41467-019-11928-w. Erratum in: Nat Commun. 2019 Oct 14;10(1):4725.

6.

Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.

Sepahi I, Faust U, Sturm M, Bosse K, Kehrer M, Heinrich T, Grundman-Hauser K, Bauer P, Ossowski S, Susak H, Varon R, Schröck E, Niederacher D, Auber B, Sutter C, Arnold N, Hahnen E, Dworniczak B, Wang-Gorke S, Gehrig A, Weber BHF, Engel C, Lemke JR, Hartkopf A, Nguyen HP, Riess O, Schroeder C.

BMC Cancer. 2019 Aug 8;19(1):787. doi: 10.1186/s12885-019-5946-0.

7.

Systematic data analysis and data mining in CatWalk gait analysis by heat mapping exemplified in rodent models for neurodegenerative diseases.

Timotius IK, Canneva F, Minakaki G, Moceri S, Plank AC, Casadei N, Riess O, Winkler J, Klucken J, Eskofier B, von Hörsten S.

J Neurosci Methods. 2019 Oct 1;326:108367. doi: 10.1016/j.jneumeth.2019.108367. Epub 2019 Jul 24. Review.

PMID:
31351096
8.

Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats.

Van Den Berge N, Ferreira N, Gram H, Mikkelsen TW, Alstrup AKO, Casadei N, Tsung-Pin P, Riess O, Nyengaard JR, Tamgüney G, Jensen PH, Borghammer P.

Acta Neuropathol. 2019 Oct;138(4):535-550. doi: 10.1007/s00401-019-02040-w. Epub 2019 Jun 26.

9.

α-Synuclein in Parkinson's disease: causal or bystander?

Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Krüger R, Müller T, Reichmann H, Rieß O, Storch A, Strobel S, van Eimeren T, Völker HU, Winkler J, Winklhofer KF, Wüllner U, Zunke F, Monoranu CM.

J Neural Transm (Vienna). 2019 Jul;126(7):815-840. doi: 10.1007/s00702-019-02025-9. Epub 2019 Jun 25. Review.

PMID:
31240402
10.

Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease.

Yu-Taeger L, Stricker-Shaver J, Arnold K, Bambynek-Dziuk P, Novati A, Singer E, Lourhmati A, Fabian C, Magg J, Riess O, Schwab M, Stolzing A, Danielyan L, Nguyen HHP.

Cells. 2019 Jun 15;8(6). pii: E595. doi: 10.3390/cells8060595.

11.

Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D.

Zwirner K, Hilke FJ, Demidov G, Socarras Fernandez J, Ossowski S, Gani C, Thorwarth D, Riess O, Zips D, Schroeder C, Welz S.

Strahlenther Onkol. 2019 Sep;195(9):771-779. doi: 10.1007/s00066-019-01478-x. Epub 2019 May 23.

PMID:
31123786
12.

Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease.

Vezzoli E, Caron I, Talpo F, Besusso D, Conforti P, Battaglia E, Sogne E, Falqui A, Petricca L, Verani M, Martufi P, Caricasole A, Bresciani A, Cecchetti O, Rivetti di Val Cervo P, Sancini G, Riess O, Nguyen H, Seipold L, Saftig P, Biella G, Cattaneo E, Zuccato C.

J Clin Invest. 2019 May 6;129(6):2390-2403. doi: 10.1172/JCI120616. eCollection 2019 May 6.

13.

Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.

Löffler MW, Mohr C, Bichmann L, Freudenmann LK, Walzer M, Schroeder CM, Trautwein N, Hilke FJ, Zinser RS, Mühlenbruch L, Kowalewski DJ, Schuster H, Sturm M, Matthes J, Riess O, Czemmel S, Nahnsen S, Königsrainer I, Thiel K, Nadalin S, Beckert S, Bösmüller H, Fend F, Velic A, Maček B, Haen SP, Buonaguro L, Kohlbacher O, Stevanović S, Königsrainer A; HEPAVAC Consortium, Rammensee HG.

Genome Med. 2019 Apr 30;11(1):28. doi: 10.1186/s13073-019-0636-8.

14.

A Diagnosis for All Rare Genetic Diseases: The Horizon and the Next Frontiers.

Boycott KM, Hartley T, Biesecker LG, Gibbs RA, Innes AM, Riess O, Belmont J, Dunwoodie SL, Jojic N, Lassmann T, Mackay D, Temple IK, Visel A, Baynam G.

Cell. 2019 Mar 21;177(1):32-37. doi: 10.1016/j.cell.2019.02.040.

PMID:
30901545
15.

Correction: Further investigation of phenotypes and confounding factors of progressive ratio performance and feeding behavior in the BACHD rat model of Huntington disease.

Clemensson EKH, Clemensson LE, Fabry B, Flunkert S, Riess O, Wronski R, Nguyen HP.

PLoS One. 2019 Mar 7;14(3):e0213755. doi: 10.1371/journal.pone.0213755. eCollection 2019.

16.

Olfactory bulb atrophy and caspase activation observed in the BACHD rat models of Huntington disease.

Lessard-Beaudoin M, Yu-Taeger L, Laroche M, Singer E, Riess O, Nguyen HHP, Graham RK.

Neurobiol Dis. 2019 May;125:219-231. doi: 10.1016/j.nbd.2019.02.002. Epub 2019 Feb 6.

PMID:
30738141
17.

Two cases of variant late infantile ceroid lipofuscinosis in Jordan.

Nafi O, Ramadan B, Riess O, Buchert R, Froukh T.

World J Clin Cases. 2019 Jan 26;7(2):203-208. doi: 10.12998/wjcc.v7.i2.203.

18.

Distinct Stress Response and Altered Striatal Transcriptome in Alpha-Synuclein Overexpressing Mice.

Wassouf Z, Hentrich T, Casadei N, Jaumann M, Knipper M, Riess O, Schulze-Hentrich JM.

Front Neurosci. 2019 Jan 10;12:1033. doi: 10.3389/fnins.2018.01033. eCollection 2018.

19.

Treadmill exercise intervention improves gait and postural control in alpha-synuclein mouse models without inducing cerebral autophagy.

Minakaki G, Canneva F, Chevessier F, Bode F, Menges S, Timotius IK, Kalinichenko LS, Meixner H, Müller CP, Eskofier BM, Casadei N, Riess O, Schröder R, Winkler J, Xiang W, von Hörsten S, Klucken J.

Behav Brain Res. 2019 May 2;363:199-215. doi: 10.1016/j.bbr.2018.11.035. Epub 2018 Dec 30.

PMID:
30599154
20.

Homozygous TBC1 domain-containing kinase (TBCK) mutation causes a novel lysosomal storage disease - a new type of neuronal ceroid lipofuscinosis (CLN15)?

Beck-Wödl S, Harzer K, Sturm M, Buchert R, Rieß O, Mennel HD, Latta E, Pagenstecher A, Keber U.

Acta Neuropathol Commun. 2018 Dec 27;6(1):145. doi: 10.1186/s40478-018-0646-6.

21.

Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3.

Schmidt J, Mayer AK, Bakula D, Freude J, Weber JJ, Weiss A, Riess O, Schmidt T.

Hum Mol Genet. 2019 May 1;28(9):1463-1473. doi: 10.1093/hmg/ddy437.

PMID:
30576445
22.

SNCA overexpression disturbs hippocampal gene expression trajectories in midlife.

Hentrich T, Wassouf Z, Riess O, Schulze-Hentrich JM.

Aging (Albany NY). 2018 Dec 13;10(12):4024-4041. doi: 10.18632/aging.101691.

23.

The movement disorder spectrum of SCA21 (ATX-TMEM240): 3 novel families and systematic review of the literature.

Traschütz A, van Gaalen J, Oosterloo M, Vreeburg M, Kamsteeg EJ, Deininger N, Rieß O, Reimold M, Haack T, Schöls L, van de Warrenburg BP, Synofzik M.

Parkinsonism Relat Disord. 2019 May;62:215-220. doi: 10.1016/j.parkreldis.2018.11.027. Epub 2018 Nov 29.

PMID:
30522958
24.

Understanding the role of genetic variability in LRRK2 in Indian population.

Kishore A, Ashok Kumar Sreelatha A, Sturm M, von-Zweydorf F, Pihlstrøm L, Raimondi F, Russell R, Lichtner P, Banerjee M, Krishnan S, Rajan R, Puthenveedu DK, Chung SJ; International Parkinson's Disease Genomics Consortium (IPDGC); Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD), Bauer P, Riess O, Gloeckner CJ, Kruger R, Gasser T, Sharma M.

Mov Disord. 2019 Apr;34(4):496-505. doi: 10.1002/mds.27558. Epub 2018 Nov 28.

PMID:
30485545
25.

Physiological and pathophysiological characteristics of ataxin-3 isoforms.

Weishäupl D, Schneider J, Peixoto Pinheiro B, Ruess C, Dold SM, von Zweydorf F, Gloeckner CJ, Schmidt J, Riess O, Schmidt T.

J Biol Chem. 2019 Jan 11;294(2):644-661. doi: 10.1074/jbc.RA118.005801. Epub 2018 Nov 19.

PMID:
30455355
26.

The BACHD rat model of Huntington disease shows slowed learning in a Go/No-Go-like test of visual discrimination.

Clemensson EKH, Novati A, Clemensson LE, Riess O, Nguyen HP.

Behav Brain Res. 2019 Feb 1;359:116-126. doi: 10.1016/j.bbr.2018.10.036. Epub 2018 Oct 29.

PMID:
30385368
27.

Mitochondrial Morphology, Function and Homeostasis Are Impaired by Expression of an N-terminal Calpain Cleavage Fragment of Ataxin-3.

Harmuth T, Prell-Schicker C, Weber JJ, Gellerich F, Funke C, Drießen S, Magg JCD, Krebiehl G, Wolburg H, Hayer SN, Hauser S, Krüger R, Schöls L, Riess O, Hübener-Schmid J.

Front Mol Neurosci. 2018 Oct 10;11:368. doi: 10.3389/fnmol.2018.00368. eCollection 2018.

28.

Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition.

Siebzehnrübl FA, Raber KA, Urbach YK, Schulze-Krebs A, Canneva F, Moceri S, Habermeyer J, Achoui D, Gupta B, Steindler DA, Stephan M, Nguyen HP, Bonin M, Riess O, Bauer A, Aigner L, Couillard-Despres S, Paucar MA, Svenningsson P, Osmand A, Andreew A, Zabel C, Weiss A, Kuhn R, Moussaoui S, Blockx I, Van der Linden A, Cheong RY, Roybon L, Petersén Å, von Hörsten S.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8765-E8774. doi: 10.1073/pnas.1807962115. Epub 2018 Aug 27.

29.

Clinical presentation and natural history of infantile-onset ascending spastic paralysis from three families with an ALS2 founder variant.

Helal M, Mazaheri N, Shalbafan B, Malamiri RA, Dilaver N, Buchert R, Mohammadiasl J, Golchin N, Sedaghat A, Mehrjardi MYV, Haack TB, Riess O, Chung WK, Galehdari H, Shariati G, Maroofian R.

Neurol Sci. 2018 Nov;39(11):1917-1925. doi: 10.1007/s10072-018-3526-8. Epub 2018 Aug 21.

PMID:
30128655
30.

First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications.

Löffler MW, Steinhilber J, Hilke FJ, Haen SP, Bösmüller H, Montes-Mojarro IA, Bonzheim I, Stäbler A, Faust U, Grasshoff U, Königsrainer I, Rammensee HG, Kanz L, Königsrainer A, Beckert S, Riess O, Schroeder C.

BMC Med Genet. 2018 Aug 15;19(1):144. doi: 10.1186/s12881-018-0651-4.

31.

Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy.

Zwirner K, Hilke FJ, Demidov G, Ossowski S, Gani C, Rieß O, Zips D, Welz S, Schroeder C.

Radiother Oncol. 2018 Dec;129(3):575-581. doi: 10.1016/j.radonc.2018.07.016. Epub 2018 Aug 7.

PMID:
30097252
32.

Novel WNT1 mutations in children with osteogenesis imperfecta: Clinical and functional characterization.

Lu Y, Ren X, Wang Y, Bardai G, Sturm M, Dai Y, Riess O, Zhang Y, Li H, Li T, Zhai N, Zhang J, Rauch F, Han J.

Bone. 2018 Sep;114:144-149. doi: 10.1016/j.bone.2018.06.018. Epub 2018 Jun 20.

PMID:
29935254
33.

Dynamic footprints of α-synucleinopathic mice recorded by CatWalk gait analysis.

Timotius IK, Canneva F, Minakaki G, Pasluosta C, Moceri S, Casadei N, Riess O, Winkler J, Klucken J, von Hörsten S, Eskofier B.

Data Brief. 2018 Jan 3;17:189-193. doi: 10.1016/j.dib.2017.12.067. eCollection 2018 Apr.

34.

The Alteration of Emotion Regulation Precedes the Deficits in Interval Timing in the BACHD Rat Model for Huntington Disease.

Garces D, El Massioui N, Lamirault C, Riess O, Nguyen HP, Brown BL, Doyère V.

Front Integr Neurosci. 2018 May 9;12:14. doi: 10.3389/fnint.2018.00014. eCollection 2018.

35.

Environmental Enrichment Prevents Transcriptional Disturbances Induced by Alpha-Synuclein Overexpression.

Wassouf Z, Hentrich T, Samer S, Rotermund C, Kahle PJ, Ehrlich I, Riess O, Casadei N, Schulze-Hentrich JM.

Front Cell Neurosci. 2018 Apr 24;12:112. doi: 10.3389/fncel.2018.00112. eCollection 2018.

36.

Dynamic nuclear envelope phenotype in rats overexpressing mutated human torsinA protein.

Yu-Taeger L, Gaiser V, Lotzer L, Roenisch T, Fabry BT, Stricker-Shaver J, Casadei N, Walter M, Schaller M, Riess O, Nguyen HP, Ott T, Grundmann-Hauser K.

Biol Open. 2018 Jul 23;7(7). pii: bio032839. doi: 10.1242/bio.032839.

37.

Pathogenic variants in E3 ubiquitin ligase RLIM/RNF12 lead to a syndromic X-linked intellectual disability and behavior disorder.

Frints SGM, Ozanturk A, Rodríguez Criado G, Grasshoff U, de Hoon B, Field M, Manouvrier-Hanu S, E Hickey S, Kammoun M, Gripp KW, Bauer C, Schroeder C, Toutain A, Mihalic Mosher T, Kelly BJ, White P, Dufke A, Rentmeester E, Moon S, Koboldt DC, van Roozendaal KEP, Hu H, Haas SA, Ropers HH, Murray L, Haan E, Shaw M, Carroll R, Friend K, Liebelt J, Hobson L, De Rademaeker M, Geraedts J, Fryns JP, Vermeesch J, Raynaud M, Riess O, Gribnau J, Katsanis N, Devriendt K, Bauer P, Gecz J, Golzio C, Gontan C, Kalscheuer VM.

Mol Psychiatry. 2019 Nov;24(11):1748-1768. doi: 10.1038/s41380-018-0065-x. Epub 2018 May 4.

PMID:
29728705
38.

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.

Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, Zachariae S, Hauke J, Wappenschmidt B, Waha A, Blümcke B, Kiechle M, Meindl A, Niederacher D, Bartram CR, Speiser D, Schlegelberger B, Arnold N, Wieacker P, Leinert E, Gehrig A, Briest S, Kast K, Riess O, Emons G, Weber BHF, Engel J, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

BMC Cancer. 2018 Mar 7;18(1):265. doi: 10.1186/s12885-018-4029-y.

39.

RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases.

Lochmüller H, Badowska DM, Thompson R, Knoers NV, Aartsma-Rus A, Gut I, Wood L, Harmuth T, Durudas A, Graessner H, Schaefer F, Riess O; RD-Connect consortium; NeurOmics consortium; EURenOmics consortium.

Eur J Hum Genet. 2018 Jun;26(6):778-785. doi: 10.1038/s41431-018-0115-5. Epub 2018 Feb 27.

40.

Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3.

Sowa AS, Martin E, Martins IM, Schmidt J, Depping R, Weber JJ, Rother F, Hartmann E, Bader M, Riess O, Tricoire H, Schmidt T.

Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2624-E2633. doi: 10.1073/pnas.1716071115. Epub 2018 Feb 23.

41.

Early Alterations in Operant Performance and Prominent Huntingtin Aggregation in a Congenic F344 Rat Line of the Classical CAGn51trunc Model of Huntington Disease.

Plank AC, Canneva F, Raber KA, Urbach YK, Dobner J, Puchades M, Bjaalie JG, Gillmann C, Bäuerle T, Riess O, Nguyen HHP, von Hörsten S.

Front Neurosci. 2018 Jan 25;12:11. doi: 10.3389/fnins.2018.00011. eCollection 2018.

42.

Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease.

Weber JJ, Kloock SJ, Nagel M, Ortiz-Rios MM, Hofmann J, Riess O, Nguyen HP.

Neuropharmacology. 2018 May 1;133:94-106. doi: 10.1016/j.neuropharm.2018.01.022.

PMID:
29355642
43.

Divalproex sodium modulates nuclear localization of ataxin-3 and prevents cellular toxicity caused by expanded ataxin-3.

Wang ZJ, Hanet A, Weishäupl D, Martins IM, Sowa AS, Riess O, Schmidt T.

CNS Neurosci Ther. 2018 May;24(5):404-411. doi: 10.1111/cns.12795. Epub 2018 Jan 9.

44.

Dynamic footprint based locomotion sway assessment in α-synucleinopathic mice using Fast Fourier Transform and Low Pass Filter.

Timotius IK, Canneva F, Minakaki G, Pasluosta C, Moceri S, Casadei N, Riess O, Winkler J, Klucken J, von Hörsten S, Eskofier B.

J Neurosci Methods. 2018 Feb 15;296:1-11. doi: 10.1016/j.jneumeth.2017.12.004. Epub 2017 Dec 16.

PMID:
29253577
45.

Reduced cell size, chromosomal aberration and altered proliferation rates are characteristics and confounding factors in the STHdh cell model of Huntington disease.

Singer E, Walter C, Weber JJ, Krahl AC, Mau-Holzmann UA, Rischert N, Riess O, Clemensson LE, Nguyen HP.

Sci Rep. 2017 Dec 4;7(1):16880. doi: 10.1038/s41598-017-17275-4.

46.

Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.

Fitzgerald JC, Zimprich A, Carvajal Berrio DA, Schindler KM, Maurer B, Schulte C, Bus C, Hauser AK, Kübler M, Lewin R, Bobbili DR, Schwarz LM, Vartholomaiou E, Brockmann K, Wüst R, Madlung J, Nordheim A, Riess O, Martins LM, Glaab E, May P, Schenke-Layland K, Picard D, Sharma M, Gasser T, Krüger R.

Brain. 2017 Sep 1;140(9):2444-2459. doi: 10.1093/brain/awx202.

PMID:
29050400
47.

Analysis of blood-based gene expression in idiopathic Parkinson disease.

Shamir R, Klein C, Amar D, Vollstedt EJ, Bonin M, Usenovic M, Wong YC, Maver A, Poths S, Safer H, Corvol JC, Lesage S, Lavi O, Deuschl G, Kuhlenbaeumer G, Pawlack H, Ulitsky I, Kasten M, Riess O, Brice A, Peterlin B, Krainc D.

Neurology. 2017 Oct 17;89(16):1676-1683. doi: 10.1212/WNL.0000000000004516. Epub 2017 Sep 15.

48.

Sequence variants in ESR1 and OXTR are associated with Mayer-Rokitansky-Küster-Hauser syndrome.

Brucker SY, Frank L, Eisenbeis S, Henes M, Wallwiener D, Riess O, van Eijck B, Schöller D, Bonin M, Rall KK.

Acta Obstet Gynecol Scand. 2017 Nov;96(11):1338-1346. doi: 10.1111/aogs.13202. Epub 2017 Sep 21.

PMID:
28815558
49.

Altered reactivity of central amygdala to GABAAR antagonist in the BACHD rat model of Huntington disease.

Lamirault C, Yu-Taeger L, Doyère V, Riess O, Nguyen HP, El Massioui N.

Neuropharmacology. 2017 Sep 1;123:136-147. doi: 10.1016/j.neuropharm.2017.05.032. Epub 2017 Jun 3.

PMID:
28587900
50.

Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies.

Vicente Miranda H, Szego ÉM, Oliveira LMA, Breda C, Darendelioglu E, de Oliveira RM, Ferreira DG, Gomes MA, Rott R, Oliveira M, Munari F, Enguita FJ, Simões T, Rodrigues EF, Heinrich M, Martins IC, Zamolo I, Riess O, Cordeiro C, Ponces-Freire A, Lashuel HA, Santos NC, Lopes LV, Xiang W, Jovin TM, Penque D, Engelender S, Zweckstetter M, Klucken J, Giorgini F, Quintas A, Outeiro TF.

Brain. 2017 May 1;140(5):1399-1419. doi: 10.1093/brain/awx056.

PMID:
28398476

Supplemental Content

Support Center